UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Mary Territo, M.D.

Specialty:

Cancer/Medical Oncology

Hematology

General Information:

Gender:	Female
Language(s):	English

Affiliation(s):

Professor, Department of Medicine, Hematology/Oncology

Physician, Department of Medicine, Hematology/Oncology, Bone Marrow/Stem Cell Transplantation Program

Director, Hematopoietic Stem Cell Transplantation

Vice Chair, Academic Affairs, UCLA Department of Medicine

Member, JCCC Cancer and Stem Cell Biology Program Area

Education:

Fellowship:	Hematology/Oncology, Harbor-UCLA Medical Center, 1971 - 1973
Residency:	Internal Medicine, Parkland Memorial Hospital, 1969 - 1971
Internship:	Medicine, Parkland Memorial Hospital, 1968 - 1969
Medical Degree:	M.D., Wayne State University School of Medicine, 1968

Certification(s):

Medical Board Certification(s):	Hematology, American Board of Internal Medicine, 1974 Internal Medicine, American Board of Internal Medicine, 1972

Contact Information:

Bone Marrow/Stem Cell Transplantation Program:	(310) 206-5789 Information and referral
UCLA Oncology Center:	(310) 206-6931 Information and patient appointments
UCLA Oncology Center:	(310) 206-6909 Information and patient appointments
Email:	mterrito@mednet.ucla.edu

Practice Information:

Clinical Interest(s):	Bone Marrow Transplantation Chronic Myelogenous Leukemia General Hematology Hematologic Malignancies Leukemia Lymphoma Multiple Myeloma Myelodysplasia

Scientific Interest(s):

Dr. Mary Territo's clinical research focuses on investigations of treatments and manipulations to improve outcomes in hematologic malignancies and hematopoietic stem cell transplantation. Studies of new antimicrobial agents have identified effective agents to help improve the infectious complications seen in patients with hematologic malignancies and hematopoietic stem cell transplantation. Studies also have looked at the effectiveness of transplantation in different disease settings and in reducing the toxicity seen post-transplantation. Trials are ongoing looking at improving the methodology for transplantation using cord blood as a source of stem cells.

Selected Cancer-Related Publications:

Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010 Jun;45(6):979-84. Epub 2010 Mar 1.

Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56.

Huynh TN, Weigt SS, Belperio JA, Territo M, Keane MP. Outcome and prognostic indicators of patients with hematopoietic stem cell transplants admitted to the intensive care unit. J Transplant. 2009;2009:917294. Epub 2009 Sep 15.

Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR, Joachim Deeg H. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007; 109(6): 2657-62.

Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, Fassas A, Snowden J, Schuening F, Myint H, Patel DD, Collier D, Heslop H, Krance R, Statkute L, Verda L, Traynor A, Kozak T, Hintzen RQ, Rose JW, Voltarelli J, Loh Y, Territo M, Cohen BA, Craig RM, Varga J, Barr WG. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum. 2006; 54(12): 3750-60.